Gyre Therapeutics, Inc. Current Liabilities
Gyre Therapeutics, Inc. (GYRE) had Current Liabilities of $28.66 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-07
- 2026-06-30: Liabilities, Current $28.66M.
- 2026-03-31: Liabilities, Current $19.79M.
- 2025-12-31: Liabilities, Current $23.78M; Liabilities, Current as first filed $18.29M.
- 2025-09-30: Liabilities, Current $15.91M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $28.66M 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $19.79M 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $23.78M 10-Q · filed 2026-08-07 | $18.29M 10-K · filed 2026-03-13 |
| 2025-09-30 | $15.91M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $16.92M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $18.99M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $19.52M 10-K · filed 2026-03-13 | |
| 2024-09-30 | $14.72M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $15.57M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $19.49M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $20.05M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $1.78M 10-Q · filed 2023-10-26 | |
| 2023-06-30 | $2.79M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $6.84M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $12.24M 10-K · filed 2024-03-27 | $16.82M 10-K · filed 2023-03-30 |
| 2022-09-30 | $1.64M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $4.31M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $13.19M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $14.16M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $17.25M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $15.57M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $14.18M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $17.80M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $16.82M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $13.66M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $11.85M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $28.90M 10-K · filed 2021-03-04 | |
| 2019-09-30 | $9.08M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $6.20M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $4.37M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $4.80M 10-K · filed 2020-02-20 | |
| 2018-09-30 | $3.30M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $2.44M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $2.90M 10-Q · filed 2018-05-03 | |
| 2017-12-31 | $8.74M 10-K · filed 2019-03-08 | |
| 2017-09-30 | $9.51M 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $9.28M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $15.22M 10-Q · filed 2017-05-11 | |
| 2016-12-31 | $21.96M 10-K · filed 2018-03-19 | |
| 2016-09-30 | $31.99M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $33.63M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $33.33M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $37.76M 10-K · filed 2017-03-08 | |
| 2015-09-30 | $37.91M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $4.25M 8-K/A · filed 2015-10-23 | $1.64M 10-Q · filed 2015-07-31 |
| 2015-03-31 | $3.90M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $2.34M 10-K · filed 2016-03-09 | $2.91M 10-K · filed 2015-03-16 |
| 2014-09-30 | $3.21M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $7.50M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $9.87M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $2.01M 8-K/A · filed 2015-10-23 | $10.98M 10-K · filed 2014-03-14 |
| 2013-09-30 | $10.64M 10-Q · filed 2013-11-06 | |
| 2013-06-30 | $8.61M 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $8.37M 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $11.35M 10-K · filed 2014-03-14 | |
| 2012-09-30 | $9.81M 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $13.07M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $48.20M 10-Q · filed 2012-05-09 | |
| 2011-12-31 | $78.61M 10-K · filed 2013-03-15 | |
| 2011-09-30 | $93.58M 10-Q · filed 2011-11-03 | |
| 2011-06-30 | $89.06M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $98.66M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |